Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week double-blind dose-response study of BPS-MR in pulmonary arterial hypertension
2009-014246-29Phase 2Completed
- Sponsor
- United Therapeutics Corporation
- Start
- Nov 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of beraprost in pulmonary arterial hypertension (PAH) (3 arms), sponsored by United Therapeutics Corporation. Primary endpoint: Change from baseline in hemodynamic parameters at week 12. Started Nov 2009; status: completed.
02
Drugs
beraprost
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2009-014246-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014246-29.